Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Medtronic PLC pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
The financial data exhibits a cyclical pattern characterized by a peak in profitability during the first half of 2022, followed by a period of margin compression throughout 2023, and a subsequent stabilization phase extending into early 2026.
- Gross Profit Margin
- A gradual contraction is observed following a peak of 67.98% in April 2022. The margin declined steadily until July 2023, after which it entered a period of relative stability, fluctuating narrowly between 64.86% and 65.51% through the remainder of the observed period.
- Operating Profit Margin
- Operational efficiency improved significantly between July 2021 and July 2022, reaching a high of 19.37%. Following this peak, the margin experienced a downward trend, hitting a low of 15.82% in April 2023. A recovery phase followed, with the margin stabilizing within the 17.00% to 17.90% range during the final quarters.
- Net Profit Margin
- The net margin demonstrated higher volatility than the gross margin. After reaching a peak of 16.75% in July 2022, it declined to a trough of 11.47% by July 2023. A steady recovery trend was established thereafter, with the margin ascending to settle at 13.20% by April 2026.
- Return on Equity (ROE) and Return on Assets (ROA)
- Both return metrics followed a highly synchronized trajectory. ROE peaked at 9.88% and ROA at 5.79% in July 2022, both subsequently declining to lows in July 2023, where ROE reached 7.07% and ROA reached 3.99%. A consistent recovery has been observed since mid-2023, with ROE returning to 9.71% and ROA to 5.16% by April 2026, signaling a restoration of capital and asset utilization efficiency.
Return on Sales
Return on Investment
Gross Profit Margin
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Gross profit margin1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Gross profit margin = 100
× (Gross profitQ4 2026
+ Gross profitQ3 2026
+ Gross profitQ2 2026
+ Gross profitQ1 2026)
÷ (Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial performance from July 2021 through April 2026 is characterized by a consistent increase in absolute gross profit and net sales, contrasted by a gradual contraction and subsequent stabilization of the gross profit margin.
- Gross Profit Margin Trajectory
- The gross profit margin initially exhibited an upward trend, peaking at 67.98% in April 2022. Following this peak, a period of steady decline occurred, with the margin dropping below 66% by April 2023. From October 2023 through April 2026, the margin entered a phase of relative stability, fluctuating within a narrow band between 64.86% and 65.51%.
- Revenue and Absolute Profit Growth
- Net sales demonstrated a long-term growth pattern, rising from 7,987 million USD in July 2021 to 9,808 million USD by April 2026. In tandem, gross profit increased from 5,389 million USD to 6,410 million USD over the same period. The simultaneous increase in both metrics indicates a growth in scale, although the declining margin suggests that the cost of goods sold increased at a rate exceeding the growth of net sales.
- Analysis of Margin Stability
- After the volatility observed between 2022 and 2023, the margin stabilized at approximately 65%. The consistency of this ratio over the final ten quarters of the analyzed period indicates that the company achieved a new equilibrium in its cost structure relative to its pricing and sales volume, effectively halting the previous downward trend.
Operating Profit Margin
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Operating profit | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Operating profit margin1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Operating profit margin = 100
× (Operating profitQ4 2026
+ Operating profitQ3 2026
+ Operating profitQ2 2026
+ Operating profitQ1 2026)
÷ (Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The operating profit margin exhibits a cyclical trend characterized by an initial expansion phase, a period of contraction, and a subsequent stabilization toward the end of the observed period. The margin began at 14.78% in July 2021 and reached a peak of 19.37% by July 2022, indicating a period of significant operational efficiency gains.
- Margin Volatility and Contraction
- Following the peak in mid-2022, a downward trend occurred, with the operating profit margin declining to 15.82% by April 2024. This contraction coincided with fluctuations in net sales, which varied between approximately 7.3 billion and 8.5 billion US dollars during this window. The decline suggests a period where operating expenses grew at a faster rate than revenue or where pricing pressures impacted profitability.
- Revenue Growth and Profit Recovery
- A recovery in profitability is evident starting in late 2024. The operating profit margin climbed back to 17.76% in January 2025 and remained relatively stable between 17.00% and 17.90% through April 2026. This recovery is strongly correlated with a substantial increase in net sales, which rose from 8.4 billion US dollars in October 2024 to a peak of 9.8 billion US dollars by April 2026.
- Operating Profit Absolute Value Trends
- Operating profit shows a general upward trajectory over the long term, increasing from 859 million US dollars in July 2021 to 1.87 billion US dollars in April 2026. While the profit margin percentages fluctuated, the absolute dollar value of operating profit reached its highest levels in the final four quarters of the period, indicating that scale expansion contributed significantly to bottom-line growth.
In summary, the financial performance is marked by an initial efficiency surge followed by a period of margin compression. However, the most recent data indicates a successful transition toward higher revenue volumes that have supported a stabilized operating margin of approximately 17-18%.
Net Profit Margin
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net income attributable to Medtronic | ||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Net profit margin1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
Net profit margin = 100
× (Net income attributable to MedtronicQ4 2026
+ Net income attributable to MedtronicQ3 2026
+ Net income attributable to MedtronicQ2 2026
+ Net income attributable to MedtronicQ1 2026)
÷ (Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The profitability profile demonstrates a period of significant volatility followed by a phase of stabilization in net profit margins. From July 2021 through April 2026, margins fluctuated between a low of 11.36% and a peak of 16.75%, reflecting varying efficiencies in converting revenue into net income.
- Margin Expansion and Contraction
- An initial upward trend in profitability is observed between July 2021 and July 2022, where the net profit margin increased from 12.29% to a peak of 16.75%. This was followed by a sustained period of contraction, with the margin declining to 11.36% by January 2024. This downward trajectory suggests a period where costs increased or pricing pressures mounted despite maintained or growing sales volumes.
- Revenue Growth Correlation
- Net sales exhibited a general growth trajectory, rising from 7,987 million US$ in July 2021 to 9,808 million US$ by April 2026. However, the net profit margin did not scale proportionally with this revenue growth; the highest margins occurred during a period of lower sales (mid-2022), while the highest sales figures in 2026 are associated with moderate margins of approximately 13.20%.
- Profitability Stabilization
- A recovery and stabilization phase is evident from April 2024 onward. During this interval, the net profit margin remained relatively steady, oscillating between 12.05% and 13.90%. This indicates a normalization of operating costs and a more consistent relationship between net income and total sales compared to the high volatility seen between 2022 and 2023.
Return on Equity (ROE)
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net income attributable to Medtronic | ||||||||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROE1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
ROE = 100
× (Net income attributable to MedtronicQ4 2026
+ Net income attributable to MedtronicQ3 2026
+ Net income attributable to MedtronicQ2 2026
+ Net income attributable to MedtronicQ1 2026)
÷ Shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The return on equity (ROE) exhibits a cyclical pattern characterized by an initial period of growth, a mid-term contraction, and a subsequent recovery toward the end of the observed period. While the ratio fluctuates, it generally oscillates between a floor of 7.07% and a ceiling of 9.88%, finishing the period with a strengthened profile of 9.71%.
- Net Income Volatility
- Net income demonstrates significant quarterly variance, acting as the primary driver for ROE fluctuations. Performance peaked early in the sequence at 1,485 million USD in April 2022 and reached a low of 427 million USD in October 2022. A secondary dip occurred in April 2024 at 654 million USD, followed by a sustained recovery reaching a high of 1,374 million USD by October 2025.
- Shareholders' Equity Shifts
- The equity base remained relatively stable between 51 and 52 billion USD from July 2021 through January 2024. A notable downward shift occurred in April 2024, where equity dropped to approximately 47.9 billion USD. For the remainder of the period, equity stabilized within the 48 to 49 billion USD range. This reduction in the equity denominator contributed to the magnification of ROE during the later quarters.
- ROE Trend Analysis
- A three-phase trend is observable in the profitability metrics. First, a growth phase occurred from July 2021 to July 2022, with ROE rising from 7.54% to 9.88%. This was followed by a contraction phase, where ROE declined to a period low of 7.07% by July 2023. Finally, a recovery phase began in October 2023, with the ratio steadily climbing and stabilizing above 9.4% from October 2025 through April 2026.
Return on Assets (ROA)
| Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net income attributable to Medtronic | ||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROA1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q4 2026 Calculation
ROA = 100
× (Net income attributable to MedtronicQ4 2026
+ Net income attributable to MedtronicQ3 2026
+ Net income attributable to MedtronicQ2 2026
+ Net income attributable to MedtronicQ1 2026)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of Return on Assets (ROA) reveals a period of volatility characterized by an initial ascent, a mid-term decline, and a subsequent recovery toward a stabilized baseline. While total assets remained relatively constant throughout the observed period, fluctuating primarily between 89.7 billion and 94.1 billion USD, the ROA percentage was driven predominantly by significant variances in quarterly net income.
- ROA Trend Trajectory
- A positive growth trend is observed from July 2021, where ROA stood at 4.23%, reaching a peak of 5.79% in July 2022. This growth was followed by a contraction phase, with the ratio descending to a low of 3.99% by July 2023. From January 2024 onward, a steady recovery is evident, with ROA climbing back above 5% and concluding the period at 5.16% in April 2026.
- Net Income Volatility
- The fluctuations in ROA correlate directly with the instability of net income attributable to Medtronic. Significant dips in profitability are noted in October 2022 (427 million USD) and April 2024 (654 million USD), which correspond with the lower bounds of the ROA figures. Conversely, peaks in net income, such as those seen in April 2022 (1,485 million USD) and October 2025 (1,374 million USD), drove the corresponding increases in asset efficiency.
- Asset Utilization Efficiency
- The stability of the total asset base suggests that changes in ROA are not the result of aggressive asset expansion or divestment, but rather a reflection of operational profitability. The ability to maintain a consistent asset base while returning to an ROA level above 5% in the final quarters indicates an improvement in the company's ability to generate profit from its existing resource base.
- Long-term Performance Pattern
- Over the full duration from July 2021 to April 2026, the ROA demonstrates a cyclical pattern. The trajectory suggests that after a period of diminished efficiency between late 2022 and mid-2023, the organization successfully implemented a recovery, sustaining a higher level of asset productivity throughout 2025 and into early 2026.